Andrew is a Director of Bioanalysis at Novartis, where he is responsible for the development, validation and implementation of preclinical and clinical PK, PD and immunogenicity assays. Prior to joining Novartis, Andrew was head of Clinical Immunology in the GlaxoSmithKline Biopharmaceuticals Unit, where he was responsible for clinical biomarker and clinical immunogenicity assays to support the biopharmaceuticals portfolio. Prior to this Andrew headed a clinical biomarker lab at GSK within the Translational Science and Genetics department.
Earlier in his career Andrew worked in a number of academic institutes, at the University of London where he was a Wellcome Trust fellow working on lymphocyte activation, as a post-doctoral fellow at University of Texas working on lymphocyte development, as a lecturer at University of Wales, working on viral immunology and as a postdoctoral fellow at the UK National Institute for Medical Research, studying dynamic interactions between host immune response and virus infections. Andrew has a PhD in Biochemistry from the University of London.